sibutramine has been researched along with Chronic Illness in 11 studies
sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin (850-1700 mg) plus sibutramine (10-20 mg, n=13) or placebo (n=15) was administered for 12 weeks in olanzapine-treated chronic schizophrenia patients." | 9.13 | Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. ( Baptista, T; Beaulieu, S; de Baptista, EA; El Fakih, Y; Galeazzi, T; Rangel, N; Uzcátegui, E, 2008) |
| "Metformin (850-1700 mg) plus sibutramine (10-20 mg, n=13) or placebo (n=15) was administered for 12 weeks in olanzapine-treated chronic schizophrenia patients." | 5.13 | Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. ( Baptista, T; Beaulieu, S; de Baptista, EA; El Fakih, Y; Galeazzi, T; Rangel, N; Uzcátegui, E, 2008) |
| "Aim of this study was to compare the effects of metformin and a body weight reduction regimen using sibutramine on insulinemia, insulin sensitivity, and ovarian function in women with anovulatory cycles or infertility." | 5.11 | Metformin versus sibutramine in the treatment of hyperinsulinemia in chronically anovulating women. ( Dravecka, I; Kraus, V; Lazurova, I; Petrovicova, J, 2004) |
| " In the late sixties, aminorex caused an epidemic of pulmonary hypertension with high mortality rates." | 4.80 | [Obesity: principles of drug therapy]. ( Ballmer, PE; Imoberdorf, R, 2000) |
| "Obesity is a chronic metabolic disorder that affects one third of American adults." | 2.44 | Pharmacotherapy for obesity. ( Aronne, LJ; Neff, LM, 2007) |
| "Obesity is a chronic disease requiring a similar long term approach to management as that of other chronic conditions." | 2.43 | Weight loss medications--where do they fit in? ( Dixon, JB, 2006) |
| "The prevalence of obesity is growing at an alarming rate." | 2.43 | Obesity. ( Fabricatore, AN; Wadden, TA, 2006) |
| "Sibutramine is a US Food and Drug Administration- and European Committee for Proprietary Medicinal Products-approved medication with demonstrated efficacy in long-term obesity management." | 2.42 | Clinical use of sibutramine. ( Ryan, DH, 2004) |
| "Obesity is epidemic and dangerous." | 2.41 | How to help your patients lose weight: current therapy for obesity. ( Weiss, D, 2000) |
| "The future of the pharmacologic treatment of obesity is promising." | 2.40 | Modern medical management of obesity: the role of pharmaceutical intervention. ( Aronne, LJ, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 10 (90.91) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ryan, DH | 1 |
| Lazurova, I | 1 |
| Dravecka, I | 1 |
| Kraus, V | 1 |
| Petrovicova, J | 1 |
| Clark, JM | 1 |
| Dixon, JB | 1 |
| Fabricatore, AN | 1 |
| Wadden, TA | 1 |
| Baptista, T | 1 |
| Uzcátegui, E | 1 |
| Rangel, N | 1 |
| El Fakih, Y | 1 |
| Galeazzi, T | 1 |
| Beaulieu, S | 1 |
| de Baptista, EA | 1 |
| Neff, LM | 1 |
| Aronne, LJ | 2 |
| Agrawal, M | 1 |
| Worzniak, M | 1 |
| Diamond, L | 1 |
| Imoberdorf, R | 1 |
| Ballmer, PE | 1 |
| Weiss, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Bioenergetic Remodeling in the Pathophysiology and Treatment of Non-Alcoholic Liver Disease[NCT03354247] | 100 participants (Anticipated) | Interventional | 2017-07-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for sibutramine and Chronic Illness
| Article | Year |
|---|---|
Clinical use of sibutramine.
Topics: Chronic Disease; Clinical Trials as Topic; Contraindications; Cyclobutanes; Female; Humans; Hyperten | 2004 |
Weight loss as a treatment for nonalcoholic fatty liver disease.
Topics: Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Chronic Disease; Cyclobutanes; Diet, R | 2006 |
Weight loss medications--where do they fit in?
Topics: Anti-Obesity Agents; Chronic Disease; Cyclobutanes; Diethylpropion; Humans; Lactones; Obesity; Orlis | 2006 |
Obesity.
Topics: Appetite Depressants; Bariatric Surgery; Behavior Therapy; Body Mass Index; Body Weight; Chronic Dis | 2006 |
Pharmacotherapy for obesity.
Topics: Amyloid; Anti-Obesity Agents; Appetite Depressants; Body Weight; Chronic Disease; Comorbidity; Cyclo | 2007 |
Modern medical management of obesity: the role of pharmaceutical intervention.
Topics: Appetite Depressants; Chronic Disease; Cyclobutanes; Enzyme Inhibitors; Humans; Lactones; Lipase; Ob | 1998 |
Managing obesity like any other chronic condition. Long-term therapy may reduce comorbidity as well.
Topics: Anti-Obesity Agents; Appetite Depressants; Chronic Disease; Contraindications; Cyclobutanes; Humans; | 2000 |
[Obesity: principles of drug therapy].
Topics: Aminorex; Anti-Obesity Agents; Appetite Depressants; Chronic Disease; Combined Modality Therapy; Cyc | 2000 |
How to help your patients lose weight: current therapy for obesity.
Topics: Anti-Obesity Agents; Antidepressive Agents; Appetite Depressants; Behavior Therapy; Chronic Disease; | 2000 |
2 trials available for sibutramine and Chronic Illness
| Article | Year |
|---|---|
Metformin versus sibutramine in the treatment of hyperinsulinemia in chronically anovulating women.
Topics: Adult; Anovulation; Appetite Depressants; Body Mass Index; Chronic Disease; Cyclobutanes; Diet, Redu | 2004 |
Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.
Topics: Adult; Antipsychotic Agents; Appetite Depressants; Benzodiazepines; Body Mass Index; Chronic Disease | 2008 |